Abstract:OBJECTIVE To investigate the diagnostic role of Anti-Mullerian Hormone (AMH) in Polycystic ovary syndrome (PCOS) using advanced marginal beta-binomial statistical model and present the optimal cut-off by different age groups, geographical locations, body mass index (BMI) and other relevant factors. DATA SOURCES A comprehensive and systematic literature search was conducted in ISI Web of Science, PubMed/Medline, Scopus, Cochrane Library, Embase and ProQuest until August 2024. STUDY ELIGIBILITY CRITERIA Epidemiological studies whose diagnostic criterion for PCOS was Androgen Excess Society (AES) or National Institute of Health (NIH) or Rotterdam were included in the current meta-analysis. If studies had information about the sensitivity and specificity of AMH or related data thorough which we could calculate these parameters and/or data on odds ratio and mean were eligible to be included. METHODS The diagnostic role of AMH was assessed using the marginal beta-binomial statistical model and summary receiver operating characteristics (SROC) method in terms of pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with 95% confidence interval (CI). Pooled weighted mean difference (WMD) and pooled odds ratios (ORs) with 95% CI were estimated using random effects model. RESULTS A total of 202 observational studies were included in the pooled analysis, of which 106 studies (including 19465 cases and 29318 controls) were used for meta-analysis of sensitivity/specificity and 186 studies (including 30656 cases and 34360 controls) for meta-analysis of mean difference. The pooled sensitivity, specificity, and DOR for AMH were 0.79 (95% CI: 0.52 to 0.97), 0.82 (95% CI: 0.64 to 0.99) and 17.12 (95% CI: 14.37 to 20.32), respectively. The area under curve (AUC) based on the SROC model was 0.90 (95% CI: 0.87 to 0.93). AMH levels were significantly higher in women with PCOS than control women (WMD= 4.91; 95% CI: 4.57–5.27). In addition, individuals with a higher level of AMH were more likely to be affected by PCOS (OR=23.17; 95% CI: 18.74-28.66; I 2 = 94%; P 5.39 ng/mL was associated with PCOS (sensitivity= 88.6%; specificity= 92.75%; likelihood ratio for a positive test result (LR+)= 12.21; and likelihood ratio for a negative test result (LR-)= 0.12). CONCLUSION According to the results of this meta-analysis, serum AMH concentration is a valuable biomarker for the diagnosis of PCOS. The cut-off points suggested by the current meta-analysis need to be evaluated and validated by future studies and before their implementation in clinical practice.

Association between anti‐Müllerian hormone levels and polycystic ovary syndrome in a general cohort of young women in Japan

Can high serum anti-Müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?

Anti-Müllerian Hormone Levels in Women with Polycystic Ovarian Syndrome Compared with Normal Women of Reproductive Age in China

Cut‐off value for anti‐Müllerian hormone in the diagnostic criteria for polycystic ovary syndrome in the Japanese population

Role of Anti-Müllerian Hormone and Testosterone in Follicular Growth: a Cross-Sectional Study.

Anti-Müllerian hormone (AMH) in the Diagnosis of Menstrual Disturbance Due to Polycystic Ovarian Syndrome

Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study

The relation between serum anti-Mullerian hormone levels and follicle count in polycystic ovary syndrome

Analysis of serum anti-Müllerian hormone levels in the main phenotypes of polycystic ovary syndrome

Assessing the clinical diagnostic value of anti-Müllerian hormone in polycystic ovarian syndrome and its correlation with clinical and metabolism indicators

Effect of the presence of polycystic ovary syndrome-related features on anti-Mullerian hormone and androstenedione levels in adolescents with or without menstrual irregularity

SUN-021 Age-Specific Multiples of the Median Level of Serum Anti-Mullerian Hormone is a Potential Marker for Diagnosis of Polycystic Ovary Syndrome

The Correlation between Sex Hormone-Binding Globulin and Clinical Characteristics According to Anti-Müllerian Hormone in Women with Regular Menstrual Cycles: A Prospective Study

Usage of AMH as a determining test of fertility in women with polycystic ovary 2 syndrome (PCOS)

New insights into the relationship between Anti-Mullerian Hormone and Polycystic ovary syndrome and its diagnostic accuracy: An updated and extended meta-analysis using marginal beta-binomial model

The Relationship between Serum Levels of Anti-Mullerian Hormone and Body Mass Index in Adolescents with Polycystic Ovary Syndrome

The Relationship Between Anti-Müllerian Hormone and Body Composition Components in Patients With Polycystic Ovary Syndrome of Reproductive Age

Anti-müllerian hormone as a diagnostic biomarker for polycystic ovary syndrome and polycystic ovarian morphology: a systematic review and meta-analysis

Age‐specific Reference Ranges of Serum Anti‐müllerian Hormone in Healthy Women and Its Application in Diagnosis of Polycystic Ovary Syndrome: a Population Study

Association of anti-Müllerian hormone and insulin resistance in adolescent girls with polycystic ovary syndrome

Association of Serum Anti-Mullerian Hormone and Free Testosterone with Different Phenotypes of Polycystic Ovary Syndrome